TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2017 -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that it will host an investor webcast to review recent achievements and corporate and product milestones over the next year. The webcast, which will take place on Tuesday, January 10, at 7 a.m. Pacific Time (10 a.m. Eastern Time), will coincide with the 35th Annual J.P. Morgan Healthcare Conference in San Francisco.
During the investor event, Portola’s senior management team will provide updates on clinical, regulatory and manufacturing milestones for its three wholly-owned product candidates, AndexXa™ (andexanet alfa), betrixaban and cerdulatinib.
AndexXa, a U.S. Food and Drug Administration (FDA)-designated Breakthrough Therapy, is in development for patients treated with a direct (apixaban, rivaroxaban or edoxaban) or indirect (enoxaparin) Factor Xa inhibitor when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding. Betrixaban, which has Fast Track designation from the FDA, is an oral Factor Xa inhibitor anticoagulant in development for the prevention of venous thromboembolism (VTE) in acute medically ill patients. Cerdulatinib, an oral, dual Syk/JAK kinase inhibitor, is in development to treat patients with resistant or relapsed hematologic cancer.
Webcast Details
To access the live investor webcast on Tuesday, January 10, at 7 a.m. Pacific Time, go to the Investor Relations section of the company’s website at http://investors.portola.com. A replay will be available for 30 days following the live event.
About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. The Company is advancing three programs, including betrixaban, an oral, once-daily Factor Xa inhibitor; AndexXa™ (andexanet alfa), a recombinant protein designed to reverse the anticoagulant effect in patients treated with an oral or injectable Factor Xa inhibitor; and cerdulatinib, a Syk/JAK inhibitor in development to treat hematologic cancers. Portola's partnered program is focused on developing selective Syk inhibitors for inflammatory conditions. For more information, visit www.portola.com and follow the Company on Twitter @Portola_Pharma.
Investor Contact: Ana Kapor Portola Pharmaceuticals [email protected] Media Contact: Julie Normart W2O Group [email protected]
